Efficacy and Tolerability of Isocitrate Dehydrogenase Inhibitors in Patients With Acute Myeloid Leukemia: A Systematic Review of Clinical Trials

Authors

Wajeeha Aiman, Saint Michael's Medical Center, New York College of Medicine, Newark, NJ, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.Follow
Muhammad Ashar Ali, New York Medical College at St. Mary's and St. Clare's, Denville, NJ, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA. Electronic address: asharalianwar94@gmail.com.Follow
Muhammad Abdul Basit, Services Institute of Medical Sciences, Lahore, Pakistan; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Zainab Omar, Dubai Medical College for Girls, Dubai, United Arab Emirates; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Muhammad Suleman, Islamic International Medical College, Rawalpindi, Pakistan; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Muhammad Hassan, Banner University Medical Center, Tucson, AZ, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Taimoor Jamil, King Edward Medical University, Lahore, Pakistan; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Muhammad Saad Anwar, King Edward Medical University, Lahore, Pakistan; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Zubair Shafique, Sahiwal Medical College, Sahiwal, Pakistan; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Gurneel Dhanesar, New York Medical College at St. Mary's and St. Clare's, Denville, NJ, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Muhammad Salman Faisal, Roswell Park Cancer Institute, Buffalo, NY, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.
Michael J. Akerman, New York Medical College at St. Mary's and St. Clare's, Denville, NJ, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.Follow
Michael Maroules, New York Medical College at St. Mary's and St. Clare's, Denville, NJ, USA; Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA.Follow
Faiz Anwer, Cancer Center, Saint Mary's General Hospital, Passaic, NJ, USA; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.Follow

Author Type(s)

Resident/Fellow, Faculty

DOI

10.1016/j.leukres.2023.107077

Journal Title

Leukemia Research

First Page

107077

Document Type

Article

Publication Date

6-1-2023

Department

Medicine

Abstract

BACKGROUND: Acute myeloid leukemia (AML) is a hematological malignancy due to anomalous differentiation and proliferation of hematopoietic stem cells with myeloid blast buildup. Induction chemotherapy is considered the first line of treatment in most patients with AML. However, targeted therapy in the form of FLT-3, IDH, BCL-2, and immune checkpoint inhibitors, can be considered as the first line depending on their molecular profile, resistance to chemotherapy, comorbidities, etc. This review aims to assess the tolerability and efficacy of isocitrate dehydrogenase (IDH) inhibitors in AML. METHODS: We searched Medline, WOS, Embase, and clinicaltrials.gov. PRISMA guidelines were followed in this systematic review. 3327 articles were screened, and 9 clinical trials (N = 1119) were included. RESULTS: In randomized clinical trials (RCTs), objective response (OR) was reported in 63-74% of the patients with IDH inhibitors + azacitidine as compared to 19-36 % of the patients with azacitidine monotherapy in newly diagnosed (ND) medically unfit patients. Survival rates were significantly improved with the use of ivosidenib. OR was reported in 39.1-46 % of the patients who relapsed/refractory to chemotherapy. ≥Grade 3 IDH differentiation syndrome and QT prolongation were reported in 3.9-10 % and 2-10 % of the patients, respectively. CONCLUSION: IDH inhibitors (ivosidenib for IDH-1 and enasidenib for IDH-2) are safe and effective in treating ND medically unfit or relapsed refractory patients with IDH mutation. However, no survival benefit was reported with enasidenib. More randomized multicenter double-blinded clinical studies are needed to confirm these results and compare them with other targeting agents.

Recommended Citation

Aiman, W., Ali, M. A., Basit, M. A., Omar, Z., Suleman, M., Hassan, M., Jamil, T., Anwar, M. S., Shafique, Z., Dhanesar, G., Faisal, M. S., Akerman, M. J., Maroules, M., & Anwer, F. (2023). Efficacy and Tolerability of Isocitrate Dehydrogenase Inhibitors in Patients With Acute Myeloid Leukemia: A Systematic Review of Clinical Trials. Leukemia Research, 129, 107077. https://doi.org/10.1016/j.leukres.2023.107077